Akums Drugs & Pharma Stock Screener | Share Price & Fundamental Analysis
AKUMS
Pharmaceuticals
Share Price NSE
₹504.90
▲
15.35 (3.14%)
Share Price BSE
₹507.25
▲
18.95 (3.88%)
Track Akums Drugs & Pharma share price live with TickJournal's free stock screener.
Analyze Akums Drugs & Pharma share price history trends and compare 52-week high low
levels.
Record your trades in TickJournal's free trading journal and track your portfolio performance.
Akums Drugs & Pharma Market Cap
₹7,854.75 Cr.
AKUMS P/E Ratio (TTM)
24.08
Akums Drugs & Pharma P/B Ratio
2.48
EPS (TTM)
₹22.60
Dividend Yield
-
Debt to Equity
0.17
AKUMS 52 Week High
₹594.00
Akums Drugs & Pharma 52 Week Low
₹414.05
Operating Margin
11.00%
Profit Margin
5.70%
AKUMS Revenue (TTM)
₹1,194.00
EBITDA
₹163.00
Net Income
₹68.00
Total Assets
₹4,113.00
Total Equity
₹3,064.00
Akums Drugs & Pharma Share Price History - Stock Screener Chart
Screen AKUMS historical share price movements with interactive charts. Analyze price trends and patterns.
Akums Drugs & Pharma Company Profile - Fundamental Screener
Screen Akums Drugs & Pharma company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for AKUMS shares.
Akums Drugs and Pharmaceuticals Limited is an Indian pharmaceutical contract development and manufacturing organization (CDMO) established in 2004. The company offers a wide range of pharmaceutical products and services both domestically and internationally. Their operations include manufacturing of Active Pharmaceutical Ingredients (APIs), sale of branded pharmaceutical formulations, formulation research and...more
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
ISIN
INE09XN01023
Website
https://www.akums.in
Akums Drugs & Pharma Balance Sheet Screener
Screen AKUMS balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Assets | ||||||
| Total Assets | 4,113 | 3,516 | 3,267 | 3,069 | 2,192 | 2,078 |
| Current Assets | 2,275 | 1,941 | 1,879 | 1,864 | 1,157 | 1,250 |
| Fixed Assets | 1,397 | 1,191 | 1,097 | 1,021 | 834 | 645 |
| Liabilities | ||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 156 | 1,585 | 1,278 | 1,172 | 725 | 627 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||
| Total Equity | 3,064 | 721 | 723 | 625 | 887 | 721 |
| Share Capital | 31 | 29 | 29 | 14 | 1 | 1 |
| Reserves & Surplus | 3,016 | 681 | 689 | 608 | 884 | 721 |
Akums Drugs & Pharma Income Statement Screener - Profit & Revenue Analysis
Screen Akums Drugs & Pharma income statement and profit fundamentals.
Analyze AKUMS quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Akums Drugs & Pharma share price evaluation.
| Item | 2025-Dec | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun | 2024-Mar | 2023-Dec | 2023-Sept | 2023-Jun |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1,194 | 1,050 | 1,051 | 1,081 | 1,030 | 1,050 | 1,026 | 955 | 1,093 | 1,188 | 978 |
| Expenses | 1,031 | 923 | 895 | 962 | 889 | 912 | 891 | 941 | 989 | 1,057 | 1,095 |
| EBITDA | 163 | 127 | 156 | 120 | 141 | 138 | 135 | 14 | 103 | 131 | -117 |
| Operating Profit % | 11.00% | 9.00% | 13.00% | 9.00% | 12.00% | 12.00% | 13.00% | 0.00% | 9.00% | 11.00% | -13.00% |
| Depreciation | 40 | 38 | 37 | 40 | 45 | 35 | 34 | 34 | 32 | 30 | 30 |
| Interest | 24 | 23 | 23 | 5 | 5 | 12 | 13 | 12 | 12 | 14 | 12 |
| Profit Before Tax | 100 | 66 | 96 | 75 | 91 | 92 | 88 | -33 | 59 | 87 | -159 |
| Tax | 32 | 23 | 31 | -75 | 25 | 25 | 26 | 7 | -136 | 54 | 29 |
| Net Profit | 68 | 43 | 65 | 150 | 66 | 67 | 61 | -40 | 195 | 33 | -187 |
| EPS | 4.33 | 2.66 | 4.15 | 9.64 | 4.26 | 4.37 | 4.21 | -2.89 | 13.21 | 2.22 | -13.16 |
Akums Drugs & Pharma Cash Flow Screener - Liquidity Fundamentals
Screen AKUMS cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2016-March | 2015-March |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | 465 | 498 | 177 | 32 | 131 | 28 | 89 | 72 |
| Investing Activities | -548 | -331 | -305 | -235 | -109 | -190 | -123 | -150 |
| Financing Activities | 73 | -108 | 125 | 236 | -92 | 233 | 37 | 66 |
| Net Cash Flow | -10 | 59 | -4 | 33 | -70 | 71 | 4 | -11 |
Akums Drugs & Pharma Shareholding Pattern Screener
See Akums Drugs & Pharma shareholding pattern with promoter, FII, and DII holdings.
Check Akums Drugs & Pharma promoter holding and ownership changes for AKUMS on TickJournal.
| Item | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Feb | 2024-Aug | 2024-Sept | 2024-Dec |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 75.26% | 75.26% | 75.26% | 75.26% | 84.91% | 75.26% | 75.26% | 75.26% |
| FII Holding | 5.77% | 4.24% | 2.28% | 1.15% | 0.00% | 5.32% | 7.34% | 6.36% |
| DII Holding | 7.40% | 8.85% | 9.28% | 14.40% | 0.00% | 7.60% | 7.52% | 7.00% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 3.41% | 3.60% | 5.01% | 5.51% | 0.00% | 4.43% | 2.11% | 3.33% |
| Other Holding | 8.16% | 8.05% | 8.18% | 3.68% | 15.09% | 7.38% | 7.77% | 8.05% |
| Shareholder Count | 69,366 | 69,424 | 75,365 | 76,869 | 8 | 138,205 | 57,531 | 68,410 |
Akums Drugs & Pharma Share Dividend Screener - Share Yield Analysis
Check Akums Drugs & Pharma dividend history with payout and yield data.
View Akums Drugs & Pharma dividend details including ex-dates and amounts for AKUMS stock.
Akums Drugs & Pharma Stock Index Membership
See which indices include Akums Drugs & Pharma stock.
Check AKUMS index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
BSE INDEX BSE HC
BSE INDEX BSEIPO
BSE INDEX SMLCAP
NIFTY 500
NIFTY IPO
NIFTY MIDSML 400
NIFTY SMLCAP 250
NIFTY TOTAL MKT
NIFTY500 EQUAL WEIGHT
NIFTY500 MULTICAP
NIFTY500 SHARIAH
Akums Drugs & Pharma Market Events Screener - Corporate Actions
Get Akums Drugs & Pharma corporate actions including splits, bonuses, and buybacks.
Check Akums Drugs & Pharma stock events that may affect AKUMS share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-02-13 | 2026-02-13 | Quarterly Result Announcement | NA | 5.56% |
| 2025-11-13 | 2025-11-13 | Quarterly Result Announcement | NA | -0.29% |
| 2025-08-08 | 2025-08-08 | Quarterly Result Announcement | NA | -4.50% |
| 2025-07-18 | 2025-07-18 | Annual General Meeting | NA | -1.09% |
| 2025-05-26 | 2025-05-26 | Quarterly Result Announcement | NA | 3.58% |
| 2025-02-06 | 2025-02-06 | Quarterly Result Announcement | NA | 0.66% |
| 2024-11-09 | 2024-11-09 | Quarterly Result Announcement | NA | -5.76% |
Akums Drugs & Pharma Competitors Screener - Peer Comparison
Screen AKUMS competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 406,351 | 37.86 | 54,729 | 9.71% | 10,980 | 37.98 |
| Divis Laboratories | 155,472 | 63.26 | 9,712 | 18.67% | 2,191 | 33.24 |
| Torrent Pharmaceuticals | 134,945 | 61.20 | 11,539 | 6.99% | 1,911 | 32.75 |
| Lupin | 103,954 | 22.26 | 22,910 | 13.74% | 3,306 | 47.35 |
| Dr Reddys Laboratories | 101,601 | 18.27 | 33,741 | 16.73% | 5,725 | 39.36 |
| Cipla | 96,320 | 21.31 | 28,410 | 7.12% | 5,291 | 26.86 |
| Zydus Life Science | 86,964 | 17.29 | 23,511 | 18.55% | 4,615 | 41.42 |
| Mankind Pharma | 82,499 | 45.81 | 12,744 | 20.90% | 2,007 | 41.40 |
| Aurobindo Pharma | 77,462 | 22.37 | 32,346 | 9.43% | 3,484 | 64.38 |
| Alkem Laboratories | 62,867 | 25.87 | 13,458 | 3.70% | 2,216 | 42.54 |
Akums Drugs & Pharma Company Announcements - News Screener
Screen AKUMS latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-03-23 | Closure of Trading Window | - |
| 2026-02-26 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-02-19 | Announcement under Regulation 30 (LODR)-Earnings Call Transcript | - |
| 2026-02-16 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | - |
| 2026-02-14 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-02-13 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-02-13 | Announcement under Regulation 30 (LODR)-Monitoring Agency Report | - |
| 2026-02-13 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-02-13 | Announcement under Regulation 30 (LODR)-Investor Presentation | - |
| 2026-02-13 | Approval Of Un-Audited Financial Results For The Quarter And Nine Months Ended 31.12.2025 | - |
| 2026-02-13 | Board Meeting Outcome for Outcome Of Board Meeting Held On 13Th February 2026 | - |
| 2026-01-31 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-01-31 | Board Meeting Intimation for Consider And Approve The Un-Audited (Standalone & Consolidated) Financial Results For The Quarter And Nine Months Ended On 31St December 2025. | - |
| 2026-01-23 | EU-GMP Certification | - |
| 2026-01-07 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2025-12-27 | Resignation Of Senior Management Personnel | - |
| 2025-12-27 | Closure of Trading Window | - |
| 2025-12-22 | Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 | - |
| 2025-12-22 | Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 | - |
| 2025-12-16 | Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Update | - |